4'-OR Nucleosides for HCV Treatment with Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infections lack effective and low-toxicity pharmaceutical agents, and there is a need for new treatments that can address the rising threat of flaviviridae infections, which often result in severe liver diseases and high mortality rates.
Innovation Solution
Development of 4′-OR nucleosides, which are compounds that display remarkable efficacy and bioavailability for treating HCV infections, including their use in preventing and treating chronic liver inflammation, cirrhosis, and other related conditions, administered alone or in combination with other anti-Flaviviridae agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for HCV are used, then some therapeutic effect is achieved, but toxicity to the host increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of nucleoside compounds, specifically creating 4'-OR nucleosides with specific substituents (R = alkyl or alkynyl) and stereochemistry (4'-alpha configuration). These structural parameter changes result in compounds that maintain antiviral efficacy against HCV while reducing host toxicity compared to existing treatments
Solution Approach 2:
The patent develops composite chemical structures by combining specific nucleobase components with modified sugar moieties (4'-OR configuration) and various substituent groups. This composite approach creates novel nucleoside analogs that achieve both therapeutic efficacy and improved safety profile
2Reliability
If new effective pharmaceutical agents are developed, then therapeutic efficacy improves, but development complexity increases
Solution Approach 1:
The patent segments the nucleoside molecule into distinct functional components: a nucleobase (adenine, guanine, cytosine, or uracil), a modified sugar ring with 4'-OR configuration, and specific substituent groups (alkyl or alkynyl at position 2'). This segmentation allows systematic exploration of structure-activity relationships while maintaining manageable molecular complexity
Solution Approach 2:
The patent creates a universal platform of 4'-OR nucleosides that can target multiple aspects of HCV infection and potentially other flaviviridae infections. The core 4'-OR structure with variable substituents provides a multi-functional scaffold that achieves both antiviral activity and reduced toxicity across different viral targets
Data Source
AI summary
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4′-OR nucleosides of Formula I:or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.